Endothelial Progenitor Cell Dysfunction in Myelodysplastic Syndromes: Possible Contribution of a Defective Vascular Niche to Myelodysplasia  by Teofili, Luciana et al.
www.neoplasia.com
Volume 17 Number 5 May 2015 pp. 401–409 401Endothelial Progenitor Cell
Dysfunction in Myelodysplastic
Syndromes: Possible Contribution
of a Defective Vascular Niche
to Myelodysplasia1,2Luciana Teofili*, 3, Maurizio Martini†, 3,
Eugenia Rosa Nuzzolo*, Sara Capodimonti*,
Maria Grazia Iachininoto*, Alessandra Cocomazzi†,
Emiliano Fabiani*, Maria Teresa Voso* and
Luigi M. Larocca†
*Istituto di Ematologia, Università Cattolica del Sacro Cuore,
Rome, Italy; †Istituto di Anatomia Patologica, Università
Cattolica del Sacro Cuore, Rome, ItalyAbstract
We set a model to replicate the vascular bone marrow niche by using endothelial colony forming cells (ECFCs), and we
used it to explore the vascular niche function in patients with low-risk myelodysplastic syndromes (MDS). Overall, we
investigated 56 patients andweobserved higher levels of ECFCs inMDS than in healthy controls;moreover,MDSECFCs
were found variably hypermethylated for p15INK4b DAPK1, CDH1, or SOCS1. MDS ECFCs exhibited a marked adhesive
capacity to normal mononuclear cells. When normal CD34+ cells were co-cultured with MDS ECFCs, they generated
significant lower amounts ofCD11b+andCD41+cells than in co-culturewith normal ECFCs.At geneexpressionprofile,
several genes involved in cell adhesionwere upregulated inMDS ECFCs, while several members of theWingless and int
(Wnt) pathways were underexpressed. Furthermore, at miRNA expression profile, MDS ECFCs hypo-expressed various
miRNAs involved inWnt pathway regulation. The addition ofWnt3A reduced the expression of intercellular cell adhesion
molecule-1 on MDS ECFCs and restored the defective expression of markers of differentiation. Overall, our data
demonstrate that in low-risk MDS, ECFCs exhibit various primary abnormalities, including putative MDS signatures, and
suggest the possible contribution of the vascular niche dysfunction to myelodysplasia.
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Homeostasis of hematopoietic system requires that hematopoietic stem
cells (HSCs) can either rest dormant or proliferate and differentiate in
response to peripheral stimuli [1]. The bone marrow (BM) environment
guarantees for these definite activities by keepingHSCs embedded within
specialized niches [2]. The BM niches are composed by several kinds of
cells, including osteoblasts and mesenchymal and endothelial cells [3–5].
The osteoblasts govern the quiescence and maintain the pool of HSCs
through specific pathways including Jagged-Notch, Tie2/angiopoietin,
and transforming growth factor β/SMAD signaling [2]. During the past
decade, several evidences have been gathered, showing that endothelial
cells also play a critical role in hematopoiesis government [5–7]. In this
study, we investigated the crosstalk between endothelial microenviron-
ment and HSCs in myelodysplastic syndromes (MDS). These clonal
disorders are characterized by an increased BMcellularity, due to excessive
apoptosis, coupled with aberrant differentiation [8]. Although MDS
constitute a very heterogeneous group of diseases, all of them share
variable degrees of ineffective hematopoiesis and susceptibility to
leukemic transformation [8]. Importantly, aberrant morphology ofmyelodysplastic cells mirrors specific functional defects, which signifi-
cantly affects the disease course also in patients at low risk for leukemic
evolution [9]. Indeed, patients with MDS are prone to serious infections
Figure 1. ECFCs in 29 patients with low IPSS risk MDS and in 17
healthy controls. MDS patients show significant higher levels of
ECFCs (1.2 vs 0.2/107 cells; P b .0001).
402 Endothelial Progenitor Cell Dysfunction in MDS Teofili et al. Neoplasia Vol. 17, No. 5, 2015evenwhen the neutrophil count is apparently preserved and they can have
serious bleeding episodes despite reasonable platelet counts [9]. In general,
MDS patients have a transient and inadequate response to chemotherapy,
probably as a result of the “dormant” status of MDS HSC within
protective BM niches [10]. Therefore, it is conceivable that BM niches
might contribute to the biologic demeanor of MDS. Because endothelial
progenitors have been proven to contribute to the BMmicrovasculature,
we used circulating endothelial colony forming cells (ECFCs) as a model
to replicate the BM vascular niche [11,12]. We isolated ECFCs from a
homogeneous group of patients diagnosed with low-risk MDS and
evaluated the influence of MDS endothelium on the differentiation of
normal hematopoietic cells.
Material and Methods
Patients
The study included 56 patients (25 males and 31 females, median
age 69 years, range 46-90) affected by low-risk MDS according to the
International Prognostic Scoring System [13]. At the time of study,
patients were not receiving antiproliferative or demethylating drugs.
Twenty-eight healthy blood donors (14 males and 14 females,
median age 61.3 years, range 45 to 77) were used as controls. All
blood samples were obtained after informed consent. The study was
approved by the Institutional Ethical Committee.
Cell Cultures
ECFCs were obtained from peripheral blood ofMDS patients or from
healthy blood donors according to the method of Ingram et al., as
previously described [14,15]. The endothelial nature of cells was
confirmed by evaluating the expression of CD34, CD146, CD45, and
vascular endothelial growth factor receptor by flow cytometry and reverse
transcription–polymerase chain reaction (PCR) [15]. Confluent ECFCs
at passages IV to VI were used for genotype profiling, hematopoietic cell
co-cultures, and flow cytometry analysis. In selected experiments,Wnt3A
or Wnt5A (R&D Systems, Space Import-Export srl, Milano, Italy) was
added at 100 ng/ml. The influence of endothelial cells on normal
hematopoietic differentiation was evaluated by co-culturing cord blood
CD34+ cells over non-irradiated ECFC layers. CD34+ cells were isolated
by immune-magnetic method with the purity always above 92%.
Co-cultures were performed in 24multiwell plates: 30 ×103 CD34+ cells
per well were seeded on confluent ECFCS in Stem Span SFEMmedium
(Stem Cell Technology Inc., Vancouver, Canada). Different cocktails of
cytokines were added to achieve the optimal commitment: 10 ng/ml each
of stem cell factor (SCF), GranulocyteMacrophage - Colony Stimulating
Factor, and Interleukin 3 for granulo-monocytic differentiation, 3 U/ml
erythropoietin and 10ng/ml SCF for erythroid differentiation, and 20 ng/
ml Interleukin 6 and 10 ng/ml thrombopoietin for megakaryocytic
differentiation (all purchased from Miltenyi Biotec GmbH, Bergisch
Gladbach, Germany). Every other day, 0.5 ml of supernatant was
removed and replaced with fresh medium plus cytokines. CD34+
cultured without ECFCs served as controls.
Flow Cytometry
The differentiation toward different lineages was assessed by flow
cytometry using a FACScanto flow cytometer (Becton-Dickinson,
Franklin Lakes, NJ) equipped with a 488-nm excitation light source.
The following monoclonal antibodies were used: phycoerytrin
(PE)-mouse anti-human CD54, fluorescein isothiocyanate anti-
human CD41a, PE anti-human CD11b, and PE anti-human CD71
(all purchased from Becton-Dickinson). Negative controls consisted ofcells incubated with isotype-matched PE- or fluorescein isothiocyanate–
conjugated irrelevant monoclonal antibodies. Results were expressed as
percentage of positive cells. The adhesive capacity of ECFCs was
assessed by evaluating the percentage of carboxyfluorescein succinimi-
dyl ester (CFSE)–labeled mononuclear cells remaining adherent to the
layer of ECFC after 2-hour incubation [15]. The expression of
intercellular cell adhesionmolecule-1 (ICAM-1) in ECFCs was assessed
with the PE anti-human CD54 (Becton-Dickinson).
Real-Time Analysis, Methylation Assay, and Gene Expression Array
Real-time analysis, methylation assay, and gene expression array are
detailed in the Supplementary Materials. All used primers and
product lengths are shown in Tables S1 and S2.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 5 software
(GraphPad Software, San Diego, CA) and MedCalc version 10.2.0.0
(MedCalc Software, Mariakerke, Belgium). Statistical comparison of
continuous variables was performed with the Mann-Whitney U test
or paired t test, as appropriate. Comparison of categorical variables
was performed using chi-square statistic and the Fisher exact test.
P values less than .05 were considered as statistically significant.
Results
MDS Patients Have a Higher Output of ECFCs than Controls
ECFCs were achieved in 29 of 56 MDS patients and in 17
of 28 controls (P = .491), with no differences in age (P = .356) and sex
(P = .651) distribution between subjects producing or not producing
ECFCs. In addition, we did not observe any clinical and biologic
differences in MDS patients with ECFC isolation frequency similar to
normal individuals (≤0.9/107 cells) and in MDS patients with ECFC
isolation frequency higher than normal individuals (N0.9/107 cells).
Among individuals with ECFCs,MDS patients had a significantly higher
number of colonies than healthy controls (1.2 vs 0.2 ECFCs/107 cells,
P b .0001, Figure 1). On the whole, the levels of ECFCs in our series of
patients and the percentage of samples producing at least one ECFC are in
good agreement with those reported by other authors using the same
methodologies [16].
ECFCs Isolated from MDS Patients Show a Hypermethylated
Phenotype
Although recent studies evidenced that in myeloproliferative neo-
plasms cells from the endothelial compartment harbor the disease-specific
signature, i.e., the JAK2V617F mutation [15,17], Della Porta et al.
demonstrated that ECFCs isolated from MDS patients do not show the
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aberrant DNAmethylation of CpG-rich promoters of a variety of genes
is very frequent in MDS [17], we investigated in ECFCs an eventual
deregulation of the epigenetic machinery. We examined in ECFC
samples obtained from 20 patients the methylation status of four genes
that frequently undergo hypermethylation inMDS hematopoietic cells:
p15INK4b (p15), DAPK1, CDH1, and SOCS1. We found that all
patients showed at least one hypermethylated gene, with 13 patients
having multiple hypermethylated genes (Table 1 and Figure 2). All
investigated genes are functional to various pathways of normal
endothelial cells, thus excluding that hypermethylation might result
from physiological gene silencing. In addition, none of 14 investigated
healthy controls was found hypermethylated.
ECFCs from MDS Patients Show Increased Adhesion to
Normal Hematopoietic Cells
It has been recently reported that mesenchymal stromal cells
(MSCs) from MDS patients have a defective expression of adhesive
molecules and chemokines [18,19], and we evaluated the proficiency
of ECFCs obtained from MDS patients to adhere to normal
mononuclear cells in comparison with ECFCs isolated from healthy
subjects. Normal mononuclear cells tracked with CFSE were
incubated over ECFC layers obtained from healthy individuals and
MDS patients: After 2 hours, non-adherent cells were discharged and
adherent cells were recovered and counted by flow cytometry. Results
obtained are shown in Figure 3. On the whole, 40 ± 4% of tracked
cells adhered to MDS ECFCs, in comparison with 13 ± 1%
remaining adherent to normal ECFCs (P = .005). Altogether, these
observations suggest that endothelial cells from MDS patients show
an “adhesion-proficient” phenotype.
The Contact with MDS Endothelial Cells Perturbs the Expansion
and Differentiation of Normal CD34+ Cells
Preliminarily, we observed that underlying ECFCs supported the
expansion and differentiation of cord blood CD34+ cells. In fact, when
CD34+ cells were seeded over normal ECFCs in erythroid,
granulo-monocytic, and megakaryocytic differentiation media, we
observed at day 7 a mean increase of 1.6 ± 0.1, 1.4 ± 0.1, and 2.0 ± 0.1
in total nucleated cell (TNC) number, respectively, compared to
cultures performed under the same conditions but without endothelial
layers. This was the result of an increase in the number of both
differentiated (i.e., CD71+, CD11b+, and CD41+) and undifferen-
tiated (i.e., CD34+) cells (Figure 4A). Accordingly, at the molecular
level, we observed the harmonized up-regulation of genes related to the
early phase of differentiation, including Friend of Gata (FOG), PU.1,
and AML-1, and subsequently, the up-regulation of genes related to
terminal differentiation, as Transferrin Receptor (TFR),Myeloperoxidase
(MPO), andGlycoprotein Ib (GPIb) (Figure 4B). Indeed, we investigated
whether MDS ECFCs had the same supportive properties exerted byTable 1. Incidence of Aberrant DNA Methylation of CpG-Rich Promoters of p15INK4b, CDH1,
DAPK1, and SOCS1 genes in ECFCs Obtained from 20 Patients with MDS and 14 Controls
Controls (n = 14) MDS Patients (n = 20) P
Methylated Unmethylated Methylated Unmethylated
p15INK4b 0 14 8 12 .01
CDH1 0 14 7 13 .026
DAPK1 0 14 3 17 ns
SOCS1 0 14 4 16 ns
One of the above 0/14 20/20 b .0001normal ECFCs. We found that ECFCs isolated from MDS patients
were scarcely able or even at all incapable to support the expansion and
differentiation of hematopoietic cells (Figure 4A). Although this defect
was apparently more evident in granulocyte and megakaryocytic
cultures than in erythroid cultures, the pattern of expression of
lineage-related genes was deeply perturbed, clearly suggesting an
imbalance between proliferation and differentiation (Figure 4B). In
particular, in granulo-monocytic and megakaryocytic cultures, line-
age-related gene expression was abnormally low in both early (PU.1 and
AML-1, respectively) and late (MPO and GPIb, respectively) phases of
differentiation. In contrast, in cells pushed toward the erythroid lineage,
FOG and TFR reached abnormally high expression values (Figure 4B).
Normal andMDS ECFCs Have Different Gene Expression Profiles
To discover the alterations underlying the impaired capability of
MDS ECFCs to sustain hematopoiesis in vitro, we evaluated through
microarray analysis their gene expression profiles in comparison with
normal ECFCs. We initially focused on genes involved in a wide
range of endothelial cell pathways, including adhesion, angiogenesis,
cell activation, cell survival, and apoptosis (the gene set is available in
the Supplementary Materials). Overall, among six significant
upregulated genes, four codified for cell adhesion molecules
[ICAM-1, vascular cell adhesion molecule 1 (VCAM-1), L-selectin
(SELL), and von Willebrand factor (vWF)]. Two additional genes
found overexpressed were nitric oxide synthase and tumor necrosis
factor ligand superfamily, member 10 (Table 2, upper section). In
contrast, matrix metalloprotease-1 (MMP1), BCL2-like 1, and CASP2
and RIPK1 domain containing adaptor with death domain were
significantly downregulated in MDS ECFCs compared to normal
controls (Table 2, upper section). Some of these genes are implicated
in the regulation of blood cell production. For example, nitric oxide
delivery not only induces megakaryocyte apoptosis and platelet
formation but also controls HSC production in embryonic and adult
lives [20–22]. Likewise, MMP1 activates the hypoxia-inducible
factor-1 pathway within niche cells, thereby inducing the transcrip-
tion of hypoxia-inducible factor–responsive genes and terminal
hematopoietic differentiation [23].
To explain our overall findings, we next examined additional
pathways with putative effects on cell adhesion. Because the Wingless
and int (Wnt) pathway is one of the main regulators of cell-to-cell
interactions in hematopoietic tissues [24–26], we evaluated the
expression profile of genes involved in the canonical and non-canon-
ical Wnt pathways (gene sets, including ligands, receptors, and target
of Wnt are available in the Supplementary Materials). We found that
Wnt canonical signaling was significantly downregulated at multiple
levels in MDS ECFCs (Table 2, middle section). Actually, MDS cells
contained low RNA levels of several Wnt ligands (Wnt3A, Wnt5A,
andWnt5B), and several Wnt target genes were hence downregulated,
including the transcriptional co-repressors amino-terminal enhancer of
split and C-terminal binding protein 1, cyclin D1, and inhibitor of
differentiation 2 [27]. On the contrary, the bone morphogenetic
protein-4 (BMP4) and follistatin (FST), which are subjected to
regulatory interactions with Wnt, were upregulated in MDS ECFCs
in comparison with normal ECFCs (Table 2, middle section).
Interestingly, both genes have specific activities in human hemato-
poiesis. In particular, BMP4 is a powerful inducer of erythroid
differentiation in stress erythropoiesis and acts in concert with SCF
and hypoxia to promote the proliferation and differentiation of
erythroid progenitors in response to acute anemia [28]. The increased
Figure 2. Methylation-specific PCR of p15INK4b (p15), DAPK1, CDH1, and SOCS1 genes in ECFCs isolated from MDS patients:
representative results of ECFCs isolated from four patients. UM indicates unmethylated gene; M indicates methylated gene; NC indicates
negative control; PC indicates positive control for unmethylated andmethylated DNA;MW indicates themolecular weight markers. Other
abbreviations are detailed in the text.
Figure 3. CFSE-labeled mononuclear cell adhesion to normal or
MDS ECFCs. (A) Percentages of mononuclear cells adherent to
ECFCs obtained from six healthy controls and from six MDS
patients. (B) Representative experiment showing on the left the
cytofluorimetric analysis of unstained peripheral blood mononu-
clear cells (negative control) and on the right the number of
CFSE-labeled mononuclear cells bound by ECFC in a healthy
control (upper panels) and in an MDS patient (lower panels).
Abbreviations are detailed in the text.
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expression of FOG and TFR during erythroid differentiation of normal
progenitors. In contrast, FST regulates the hematopoietic cell
adhesiveness to fibronectin, favoring the expansion of immature
progenitors [29]. We hypothesized that the extensive hypo-expression
of several Wnt genes could depend on the aberrant hypermethylation of
their promoters. Nevertheless, our search for methylation of theWnt5A
gene promoter region was unsuccessful (data not shown). We then
investigated the expression profile of a set of 84miRNAswith predictable
effects on the Wnt pathway. Actually, we demonstrated that, in
comparison with normal ECFCs, MDS ECFCs contained significantly
lower amounts of miR-142-3p, miR-424-5p, and miR-196b-5p
(Table 2, lower section). Whereas all these miRNAs are variously
involved in hematopoiesis [30,31] or angiogenesis [32], the low levels of
miR-142-3p were particularly interesting, because it has been
demonstrated to modulate the Wnt pathway to balance proliferation
and differentiation ofmesenchymal cells [33]. Interestingly,miR-142-3p
was predicted to inhibit the expression of BMP4 at both “Ingenuity” and
“microRNA.org-Target and Expression” software.
The Addition of Soluble Wnt3A Modifies the Adhesive Profile
of MDS ECFCs
Overall, the analysis of gene expression profiles suggested that MDS
endothelial progenitor cells show a defective expression of several Wnt
pathway constituents. Previous studies demonstrated that canonical Wnt
pathway signaling regulates hematopoietic homeostasis by shaping the
niches supportive of hematopoietic stem/progenitor cells [25]. In
particular, Wnt signaling modulates VCAM-1 expression by marrow
stromal cells and controls the production of extracellular matrix
components [34]. Therefore, our model suggests that the increased
adhesiveness of MDS ECFCs may result from the ineffective Wnt
signaling and that the aberrant attachment of hematopoietic cells to the
endothelial environment could interfere with their normal differentiation
programs. To test this hypothesis, we investigated whether the addition
of 100 ng/ml of soluble Wnt3A and/or Wnt5A to ECFC cultures
could influence the abnormally high RNA expression of ICAM-1,
VCAM-1, vWF, and SELL.We observed that ICAM-1 RNA expression
was the most significantly affected: either Wnt3A or Wnt5A was able
to reduce ICAM-1 expression, but Wnt3A induced a more sustained
and deep decrease (Figure 5A). These findings were further confirmed by
flow cytometry. In particular, we found a significant reduction of
ICAM-1 expression in MDS ECFC but not in normal ECFC after
Wnt3A addition (Figure 5, B and C). In addition, we investigated
Figure 4. Co-cultures of normal cord blood CD34+ cells in the absence of endothelial layers or over ECFC obtained from healthy controls
and from MDS patients. Results represent the mean of six experiments. (A) Day 7 concentrations of total nucleated cells, CD71+ or
CD11b+ or CD41+ cells, and CD34+ cells in cultures supporting erythroid, granulo-monocytic, and megakaryocytic differentiation,
respectively. (B) Real-time PCR expression of early (FOG, PU.1, and AML-1) and late differentiation markers (TFR,MPO, and GPIb) in cells
recovered at days 4 and 7 from the experiments illustrated in A. *P b .05; **P b .005; ***P b .001. refers to cultures without ECFCs;
refers to cultures with normal ECFCs; refers to cultures with MDS ECFCs.
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support hematopoietic differentiation. We found that the expression
pattern of differentiation markers was positively affected by the Wnt3A
addition, with a significant decrease in abnormally high TRF RNA
values and a significant increase in both MPO and GPIb RNA
expression (Figure 5D).
Discussion
This study demonstrates that endothelial progenitor cells isolated
from patients with low-risk MDS have an increased adhesioncapacity and fail to adequately sustain hematopoiesis, particularly
in myeloid and megakaryocyte differentiation. Although the
increased level of ECFCs in these patients has been previously
reported [16], our findings suggest that the molecular defects
underlying MDS endothelial progenitor dysfunctions are likely
primary in their nature, since these cells differ from their normal
counterparts in both genetic and epigenetic profiles. Since the
transplant of allogeneic endothelial progenitor cells in myelosuppressed
mice shortens the duration of aplasia and fosters blood cell recovery, it is
conceivable that circulating ECFCs normally contribute to the BM
Table 2. Genes Differentially Expressed in ECFCs Isolated from MDS Patients and Healthy
Controls. The Upper Section Includes Genes Functional to Adhesion, Angiogenesis, Activation
Survival, and Apoptosis of Endothelial Cells; the Middle Section Includes Genes Belonging to th
Wnt Pathway, and the Lower Section Includes miRNAs
Gene Fold Regulation P
ICAM-1 14.06 .012
Constitutive nitric oxide synthase 3 13.17 .015
SELL 7.26 .041
Tumor necrosis factor ligand superfamily, member 10 11.08 .019
VCAM-1 5.46 .008
vWF 6.86 .001
BCL2-like 1 −8.51 .006
CASP2 and RIPK1 domain containing adaptor with death domain −4.92 .032
MMP1 −4.78 .002
FST 5.38 .043
BMP4 4.85 .001
Amino-terminal enhancer of split −4.48 .001
Cyclin D1 −5.59 .004
C-terminal binding protein 1 −4.32 .003
Inhibitor of differentiation 2 −4.96 .024
Wnt3A −4.54 .010
Wnt5A −4.51 .021
Wnt5B −83.51 .031
miR-142-3p −6.99 .003
miR-424-5p −4.33 .001
miR-196b-5p −9.89 .033
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emicrovasculature homeostasis [35]. Even though our observations have
been gathered in an in vitromodel where ECFCs represent the surrogate
of the BM vascular niche, they suggest a possible “diseased vascular
niche” in low-risk MDS patients.
The relevant role of endothelial cells in hematopoiesis was clearly
demonstrated several decades ago by Knospe et al. [36]. At that time,
the authors showed that in mice subjected to local BM curettage
followed by radiation and HSC transplantation the earliest foci of
hematopoiesis occurred just into the areas of sinusoidal vascular
regeneration [36]. Subsequent studies highlighted that the engraft-
ment and reconstitution of hematopoiesis are mediated by vascular
endothelial growth factor receptor 2 through the regeneration of
sinusoidal endothelial cells [37]. While these effects have been partly
attributed to the secretion of soluble growth factors, additional
evidences indicate that the direct contact between HSCs and
endothelial cells is relevant to hematopoiesis regulation. For instance,
the contact with HSCs triggers in endothelial cells the activation
of Akt and the release of paracrine factors that balance HSC
self-renewal and differentiation [38]. Similarly, in normal BM, the
areas of SCF/c-kit–mediated hematopoiesis are in tight spatial
co-localization with endothelial and perivascular cells [39]. In
addition, E-selectin expressed by endothelial cells has been recently
recognized as a new regulator of HSC proliferation and differenti-
ation [40]. We show here that, in contrast to normal ECFCs,
circulating endothelial cells obtained from low-riskMDS patients are
scarcely efficient in supporting hematopoietic differentiation: This
defect is associated to the increased adhesion to hematopoietic cells
that is likely induced by the low expression of various members of the
Wnt pathway. In particular, stromal Wnt3A has been indicated as a
powerful negative regulator of several adhesion molecules, including
ICAM-1 and VCAM-1 [34], and in our experiments, the addition of
exogenous Wnt3A both reduced ICAM-1 expression and partially
restored cell differentiation.The microenvironment participation in determining clinical and
biologic features of MDS has been extensively investigated. Tennant
et al. first showed that the adherent layers obtained from BM of MDS
patients were significantly defective in supporting hematopoiesis in
long-term Dexter-type cultures [41]. Tauro et al. observed hete-
rogeneous abnormalities of MDS stromal cells including altered
matrix molecule expression and changes in superoxide production,
possibly contributing to the abnormal survival and development of
hematopoietic cells [42]. Moreover, BM stromal cells of MDS
patients exhibit abnormal production of several cytokines contribut-
ing to the impaired immune function observed in these patients [43].
More recently, Ferrer at al. showed that primary MSCs obtained from
MDS patients express low levels of adhesion and cell surface
molecules and, when co-cultured with CD34+ cells from healthy
donors, produce lower numbers of cobblestone area–forming cells
and fewer colony-forming units [18]. Similarly, Geyh et al. found that
MSCs from patients with all MDS subtypes exhibit impaired growth
and osteogenic differentiation, associated with specific methylation
patterns and altered expression of several molecules involved in the
interaction with HSCs, including osteopontin, Jagged1, Kit-ligand,
and angiopoietin as well as several chemokines [19]. Finally, Pavlaki
et al. observed that MSCs obtained from low- to intermediate-risk
patients displayed downregulated canonical Wnt pathway due to
up-regulation of inhibitors [44]. When pharmacologically activated,
Wnt signaling led to an increased cell proliferation and restored their
osteogenic differentiation ability [44]. The findings obtained in our
model suggest for the first time that specific primitive perturbations
could occur also at the level of the MDS vascular niche. Primitive
abnormalities of endothelial cells or endothelial cell progenitors have
been previously demonstrated in chronic myeloproliferative neo-
plasms. In these conditions, the “diseased vascular niche” facilitates
clonal stem cell proliferation, favors extramedullary hematopoiesis
through mobilization and homing of neoplastic HSCs in new niches
in the spleen, and contributes to vascular complications [15,45,46].
In contrast, in MDS patients, endothelial niche dysfunctions could
sustain BM hypercellularity embedded in dense microvasculature
scaffolds. In addition, the pathologic involvement of the circulating
endothelial compartment might be implicated in the association
between MDS with systemic vasculitis [47] or in thrombotic
proficiency of MDS patients subjected to specific therapies despite
concomitant thrombocytopenia [48].
The canonical and non-canonical Wnt pathways consist of a
complex network of interrelated and reciprocally connected
signals [24–26]. Previous studies carried out in MDS hematopoi-
etic cells reported hypermethylation of several Wnt antagonists,
contributing to the activation of the Wnt pathway and the
expression of β-catenin [49,50]. In these patients, a correlation
between risk of leukemic transformation and nuclear β-catenin
expression or Wnt antagonist hypermethylation was noticed,
confirming the linkage between Wnt pathway activation and
leukemogenesis [49,50]. Our observations, in contrast, suggest that
the defective function of the Wnt pathway in vascular niches could
mainly affect the physiological differentiation processes of
hematopoietic cells, resulting in the myelodysplasia observed also
in patients at low risk for leukemic transformation. Accordingly,
harvest of immature progenitors (i.e., CD34+ cells) in cultures
supported by MDS endothelial cells was not so different from that
obtained in the presence of normal endothelial cells. Furthermore,
we found that supplementation of exogenousWnt3A to cultures
Figure 5. (A) Real-time PCR expression of VCAM-1, vWF, and ICAM-1 RNA inMDS ECFCs incubated withWnt3A, Wnt5A, andWnt3A plus
Wnt5A (each at 100 ng/ml concentration). The data represent the mean values of three experiments (SDs are b10% and have been
omitted). (B and C) The flow cytometry expression of ICAM-1 in normal (gray line) and MDS (red line) ECFCs without Wnt3A (B) and after
incubation with Wnt3A (C). We observed a significant reduction of ICAM-1 in MDS ECFCs. Data refer to a representative experiment;
mean fluorescence intensity is reported in the x axis and number of events in the y axis. (D) Co-cultures of normal cord blood CD34+ cells
with normal ECFCs (white columns), MDS ECFCs (red columns), or MDS ECFCs plus 100 ng/ml Wnt3A (gray columns). Real-time PCR
expression of TRF,MPO, and GPIb RNA after day 7 of culture in erythroid, granulo-monocytic, and megakaryocytic differentiating media.
Results represent the mean of five experiments. *P b .05; ***P b .001.
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hematopoietic cells.
Conclusion
Overall, our observations add a new tile to the complex mosaic of the
MDS pathogenesis and offer an innovative perspective on thesediseases, pointing to the primary dysfunctions of the vascular niche as
important drivers for myelodysplasia.
Appendix A. Supplementary Materials
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.04.001.
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